Merck’s Q3 2026: A Broad Portfolio Delivers, One-Time Charge Hangs Over EPS, and a Pipeline That Could Outlive the Quarter

ticker MRK posts its third-quarter 2026 earnings with a hard look at EPS, revenue forecast, and whether the market should care more about a one-time charge than a healthy share of topline growth. The company reports total worldwide sales of $18.1 billion, up 5% year over year (4% growth ex-FX). GAAP EPS lands at $2.04 and Non-GAAP EPS at $2.49, both including a $0.12 per-share one-time charge tied to a global licensing agreement. Analysts will weigh these numbers against the EPS consensus and ask whether there was an earnings surprise in the mix, given the pressure and promise across Merck’s portfolio.

What Merck reported in Q3 2026

Total worldwide sales: $18.1 billion, up 5% (4% ex-FX).
Keytruda/KEYTRUDA QLEX sales: $8.6 billion, up 6% (6% ex-FX); includes KEYTRUDA QLEX sales of $830 million.
WINREVAIR sales: $694 million, up 93% (94% ex-FX).
Animal Health sales: $1.7 billion, up 4% (3% ex-FX).
EPS: GAAP EPS $2.04; Non-GAAP EPS $2.49. Both metrics include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch.
Full-year 2026 revenue forecast: Merck narrows and raises the midpoint to a range of $66.8 billion to $67.3 billion.

In short, the top line looks sturdy, the big-selling immunotherapy continues to drive a chunk of the story, and the bottom line carries a tax-like windfall of a single one-time hit. Whether investors treat that as a drag on GAAP numbers or a footnote to a broader growth narrative will depend on how the street views the non-GAAP adjustment and the trajectory of Keytruda's sales in a crowded field.

Pipeline & Portfolio Highlights

A cross-portfolio update at ESMO 2026 underscores Merck’s attempt to turn near-term catalysts into longer-term growth. Highlights include:

TroFuse-005: Sacituzumab Tirumotecan (sac-TMT) in certain advanced or recurrent endometrial cancer; U.S. FDA accepted for priority review a Biologics License Application based on these data.
INTerpath-001: Intismeran Autogene plus KEYTRUDA as adjuvant treatment for resected stage IIB-IV melanoma, in collaboration with Moderna.
Tulisokibart: Positive Phase 2b results in hidradenitis suppurativa.
BRUNELLO: One-year results from a trial evaluating Remigromig in adults with diabetic macular edema.

The tone of these updates is less about a single blockbuster and more about breadth—multiple shotguns of potential in oncology and immunology, with regulatory attention on some early-stage bets.

Outlook, Implications, and Sector Peers

Merck’s decision to tighten its revenue forecast while widening the expected range signals a confident view of its sales engine, even as it wrestles with one-time charges that affect GAAP metrics. The revised revenue forecast, centered around a midpoint that nudges higher, implies management sees consistent demand beyond a single product cycle. The blend of a durable top line, ongoing Keytruda momentum, and a pipeline with several near-term catalysts could set a template for sector peers who balance legacy franchises with new modalities.

For industry peers, the message is nuanced: maintain a robust commercial platform while managing the math of one-time items that can cloud quarterly EPS narratives. If Merck’s pipeline data translates into regulatory milestones and eventual launches, the stock could re-rate on the basis of long-run growth rather than quarterly beat-the-street noise. Conversely, if regulatory hurdles or competitive dynamics intensify, the same pipeline breadth may not translate into commensurate upside, a risk that sector investors should monitor alongside gross margins and currency effects.

Investor Takeaways

MRK remains a diversified growth bet, with Keytruda continuing as a substantial contributor to sales alongside a broader portfolio in oncology and animal health.
The one-time charge tied to a licensing deal dampens GAAP EPS but is disclosed up front; non-GAAP metrics still play a critical role for evaluating ongoing profitability.
The updated revenue forecast suggests confidence in mid-term demand, even as the company navigates competitive and regulatory dynamics in its key franchises.
Pipeline progress—especially pivotal data and regulatory-initiated reviews—offers potential near-term catalysts that could influence sector peers if similar patterns emerge across big pharma.
Analysts will test whether the EPS figures align with consensus, and whether any earnings surprise is driven by the top line or the bottom-line adjustments.